ForPatients
by Roche

Alzheimer's Disease (AD)

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

Trial Status	Trial Runs In	Trial Identifier
Terminated	27 Countries	NCT03114657 2016-003288-20 BN29553

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (Q4W) for 100 weeks. The primary efficacy assessment will be performed at 105 weeks. The participants who do not enter open-label extension will enter for a long term follow-up period for up to 52 weeks after the last crenezumab dose (Week 153).

Hoffmann-La Roche	Phase 3
Sponsor	Phase

NCT03114657 2016-003288-20 BN29553
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>= 50 Years & <= 85 Years	No